Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) filed a Form 8-K on August 7, 2024, to announce its financial results for the second quarter ended June 30, 2024. The company is a biopharmaceutical firm incorporated in Delaware with principal executive offices in South San Francisco, CA.
Key Financial Metrics
This Form 8-K serves as a notification of the press release (Exhibit 99.1) containing the detailed financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. It solely references the issuance of the Q2 2024 results press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in this Current Report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other filings. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2024) for actual Q2 2024 financial figures.
- Verify the company's cash runway and burn rate in the full press release, as this 8-K does not list liquidity metrics.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the press release.
- Note that the information in this 8-K is not incorporated by reference into other SEC filings.